Institut Investigacio Sanitaria Pere Virgili
Quick facts
Marketed products
- Niacin plus laropiprant · Cardiovascular
Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks prostaglandin D2 receptors to reduce niacin-induced flushing.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: